{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:22:11Z","timestamp":1793154131690,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Wild-type and hereditary transthyretin-mediated amyloidosis (ATTRwt and ATTRv amyloidosis, respectively) are progressive, fatal diseases with a broad range of clinical presentations and multisystem effects. Despite having a higher prevalence, ATTRwt amyloidosis is less well characterized due to its non-hereditary nature, and its relatively poorer disease awareness delays diagnosis. Understanding of its natural history has evolved in recent years, but this is largely based on physician-collected data rather than patients\u2019 reports of their own experiences. A mixed methods approach was used to evaluate how the healthcare journeys of patients with ATTRv and ATTRwt amyloidosis compare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A quantitative survey was administered to US-patients diagnosed with both ATTRwt amyloidosis and ATTRv amyloidosis identified through a patient support group. Subsequent in-depth interviews with participants with ATTRwt amyloidosis were conducted. Quantitative data with related qualitative quotes from patients were produced to characterize their paths to diagnosis and the disease burden experienced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 47 respondents completed the survey (ATTRv, n\u2009=\u200920 and ATTRwt, n\u2009=\u200927) and a total of 14 survey respondents with ATTRwt amyloidosis were interviewed. Survey results reported a high disease burden for patients with both conditions, with patients with ATTRwt amyloidosis reporting more diagnoses and procedures prior to their final diagnosis. Interviews with participants with ATTRwt amyloidosis revealed that patients face a high symptomatic burden of disease. Diagnosis was often delayed due to three key factors: (1) early signs of ATTRwt amyloidosis were often assumed to be related to old age; (2) many medical specialists working in silos were involved in participants\u2019 diagnostic; and (3) there was a general lack of disease awareness. Early indicators such as carpal tunnel syndrome were often overlooked. Participants were typically diagnosed after the disease had progressed to include severe cardiac symptoms such as atrial fibrillation and severe shortness of breath. Sleep apnoea was also reported by a number of participants, with a considerable impact on quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study provides insight into the overall impact of the patient journey on their quality of life and demonstrates how increased awareness of ATTRwt amyloidosis and more coordinated engagement with physicians could reduce the time to diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03407-3","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T16:18:55Z","timestamp":1731082735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement"],"prefix":"10.1186","volume":"19","author":[{"given":"Chafic","family":"Karam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5561-9738","authenticated-orcid":false,"given":"Colleen","family":"Moffit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline P.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran M.","family":"Kochman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Weijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Puls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Schurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"issue":"3","key":"3407_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/13506129.2022.2035354","volume":"29","author":"T Damy","year":"2022","unstructured":"Damy T, Adams D, Bridoux F, et al. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid. 2022;29(3):165\u201374. https:\/\/doi.org\/10.1080\/13506129.2022.2035354.","journal-title":"Amyloid"},{"issue":"5","key":"3407_CR2","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/ehf2.12793","volume":"7","author":"D Dang","year":"2020","unstructured":"Dang D, Fournier P, Cariou E, et al. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. 2020;7(5):2418\u201330. https:\/\/doi.org\/10.1002\/ehf2.12793.","journal-title":"ESC Heart Fail"},{"key":"3407_CR3","unstructured":"BusinessWire. Alnylam Pharmaceuticals announces initiation of APOLLO-B phase 3 study of Patisiran for the treatment of transthyretin amyloidosis with cardiomyopathy. 2019. Accessed 21 June 2023. Available from: https:\/\/www.businesswire.com\/news\/home\/20190916005255\/en\/Alnylam-Pharmaceuticals-Announces-Initiation-of-APOLLO-B-Phase-3-Study-of-Patisiran-for-the-Treatment-of-Transthyretin-Amyloidosis-with-Cardiomyopathy"},{"issue":"1","key":"3407_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/13506129.2011.574354059","volume":"181","author":"L Connors","year":"2011","unstructured":"Connors L, Doros G, Sam F, et al. Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid. 2011;181(1):157\u20139. https:\/\/doi.org\/10.3109\/13506129.2011.574354059.","journal-title":"Amyloid"},{"key":"3407_CR5","unstructured":"Orpha.net. Wild type ATTR amyloidosis. Accessed 15 May 2023. Available from: https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=EN&data_id=21955"},{"issue":"7 Suppl","key":"3407_CR6","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107-s112.","journal-title":"Am J Manag Care"},{"issue":"2","key":"3407_CR7","doi-asserted-by":"publisher","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","volume":"2","author":"J Pinney","year":"2013","unstructured":"Pinney J, Whelan C, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2):e000098. https:\/\/doi.org\/10.1161\/JAHA.113.000098.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"3407_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"L Connors","year":"2016","unstructured":"Connors L, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective. Observ Cohort Study Circ. 2016;133(3):282\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018852.","journal-title":"Observ Cohort Study Circ"},{"issue":"2","key":"3407_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"P Swiecicki","year":"2015","unstructured":"Swiecicki P, Zhen D, Mauermann M, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123\u201331. https:\/\/doi.org\/10.3109\/13506129.2015.1019610.","journal-title":"Amyloid"},{"issue":"2","key":"3407_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"F Ruberg","year":"2012","unstructured":"Ruberg F, Maurer M, Judge D, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2012.04.015.","journal-title":"Am Heart J"},{"issue":"9","key":"3407_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"P Sattianayagam","year":"2012","unstructured":"Sattianayagam P, Hahn A, Whelan C, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehr383.","journal-title":"Eur Heart J"},{"issue":"10","key":"3407_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"3407_CR13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","volume":"108","author":"F AusdemSiepen","year":"2019","unstructured":"AusdemSiepen F, Hein S, Prestel S, et al. Carpal tunnel syndrome and spinal canal stenosis: Harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol. 2019;108(12):1324\u201330. https:\/\/doi.org\/10.1007\/s00392-019-01467-1.","journal-title":"Clin Res Cardiol."},{"issue":"2","key":"3407_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2217\/ahe.13.10","volume":"9","author":"R Givens","year":"2013","unstructured":"Givens R, Russo C, Green P, et al. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health. 2013;9(2):229\u201335. https:\/\/doi.org\/10.2217\/ahe.13.10.","journal-title":"Aging Health"},{"issue":"30","key":"3407_CR15","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"J Gillmore","year":"2018","unstructured":"Gillmore J, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589.","journal-title":"Eur Heart J"},{"issue":"1","key":"3407_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169.","journal-title":"Circulation"},{"issue":"6","key":"3407_CR17","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beir\u00e3o JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109\u201322. https:\/\/doi.org\/10.1007\/s00415-019-09688-0.","journal-title":"J Neurol"},{"key":"3407_CR18","unstructured":"Amyloidosis Foundation. Wild-type ATTR. 2022. Accessed 02 May 2023. Available from: https:\/\/amyloidosis.org\/facts\/wild-type\/"},{"key":"3407_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/17531934231218997","author":"J Brunet","year":"2023","unstructured":"Brunet J, Rabarin F, Maugendre E, et al. Prevalence of transthyretin amyloidosis in patients undergoing carpal tunnel surgery: a prospective cohort study and risk factor analysis. J Hand Surg Eur. 2023. https:\/\/doi.org\/10.1177\/17531934231218997.","journal-title":"J Hand Surg Eur"},{"issue":"1","key":"3407_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ehf2.14173","volume":"10","author":"B Ladefoged","year":"2023","unstructured":"Ladefoged B, Clemmensen T, Dybro A, et al. Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS). ESC Heart Fail. 2023;10(1):234\u201344. https:\/\/doi.org\/10.1002\/ehf2.14173.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"3407_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacc.2019.04.054","volume":"74","author":"EL Fosb\u00f8l","year":"2019","unstructured":"Fosb\u00f8l EL, R\u00f8rth R, Leicht BP, et al. Association of carpal tunnel syndrome with amyloidosis, heart failure, and adverse cardiovascular outcomes. J Am Coll Cardiol. 2019;74(1):15\u201323. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.054.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"3407_CR22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022.","journal-title":"J Am Coll Cardiol"},{"key":"3407_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","volume":"21","author":"M Gertz","year":"2020","unstructured":"Gertz M, Adams D, Ando Y, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21:198. https:\/\/doi.org\/10.1186\/s12875-020-01252-4.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"3407_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40120-022-00414-z","volume":"12","author":"T Coelho","year":"2023","unstructured":"Coelho T, Waddington Cruz M, Chao CC, et al. Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen. Neurol Ther. 2023;12(1):267\u201387. https:\/\/doi.org\/10.1007\/s40120-022-00414-z.","journal-title":"Neurol Ther"},{"issue":"1","key":"3407_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/13506129.2022.2118043","volume":"30","author":"D Quan","year":"2023","unstructured":"Quan D, Obici L, Berk JL, et al. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid. 2023;30(1):49\u201358. https:\/\/doi.org\/10.1080\/13506129.2022.2118043.","journal-title":"Amyloid"},{"key":"3407_CR26","doi-asserted-by":"crossref","unstructured":"Lousada I, Maurer M, Guthrie S, et al. Amyloidosis research consortium cardiac amyloidosis survey: results from patients with AL amyloidosis and their caregivers. In: European Hematology Association 22nd Annual Congress. Madrid; 2017.","DOI":"10.1016\/S0735-1097(18)31431-1"},{"key":"3407_CR27","unstructured":"Lindmark K, Garc\u00eda-Pav\u00eda P, Zikry M, et al. Why the diagnosis of ATTR-cardiomyopathy may be a challenge for physicians European Society of Cardiology (ESC) Congress. Paris; 2019."},{"issue":"4","key":"3407_CR28","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/ehf2.13473","volume":"8","author":"T Inomata","year":"2021","unstructured":"Inomata T, Tahara N, Nakamura K, et al. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm. ESC Heart Fail. 2021;8(4):2647\u201359. https:\/\/doi.org\/10.1002\/ehf2.13473.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"3407_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13023-020-01623-1","volume":"16","author":"M Vera-Llonch","year":"2021","unstructured":"Vera-Llonch M, Reddy SR, Chang E, et al. The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis. Orphanet J Rare Dis. 2021;16(1):25. https:\/\/doi.org\/10.1186\/s13023-020-01623-1.","journal-title":"Orphanet J Rare Dis"},{"key":"3407_CR30","unstructured":"Amyloidosis Support Groups. About Amyloidosis Support Groups. 2023. Accessed 06 June 2023. Available from: https:\/\/www.amyloidosissupport.org\/about.html"},{"key":"3407_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59020335","author":"I Kuznecova","year":"2023","unstructured":"Kuznecova I, Mierkyte G, Janciauskas D, et al. Impact of carpal tunnel syndrome surgery on early diagnosis and treatment of transthyretin cardiac amyloidosis. Medicina (Kaunas). 2023. https:\/\/doi.org\/10.3390\/medicina59020335.","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"3407_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","volume":"80","author":"O Westin","year":"2022","unstructured":"Westin O, Fosb\u00f8l EL, Maurer MS, et al. Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome. J Am Coll Cardiol. 2022;80(10):967\u201377. https:\/\/doi.org\/10.1016\/j.jacc.2022.06.026.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3407_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1164\/ajrccm.163.1.2001008","volume":"163","author":"E Shahar","year":"2001","unstructured":"Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163(1):19\u201325. https:\/\/doi.org\/10.1164\/ajrccm.163.1.2001008.","journal-title":"Am J Respir Crit Care Med"},{"key":"3407_CR34","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2020.1329","author":"N Gupta","year":"2020","unstructured":"Gupta N, Agrawal S, Goel AD, et al. Profile of sleep disordered breathing in heart failure with preserved ejection fraction. Monaldi Arch Chest Dis. 2020. https:\/\/doi.org\/10.4081\/monaldi.2020.1329.","journal-title":"Monaldi Arch Chest Dis."},{"issue":"3","key":"3407_CR35","doi-asserted-by":"publisher","first-page":"220153","DOI":"10.1183\/20734735.0153-2022","volume":"18","author":"S Matthes","year":"2022","unstructured":"Matthes S, Randerath W. Assessment of sleep disordered breathing in patients with heart failure. Breathe (Sheff). 2022;18(3):220153. https:\/\/doi.org\/10.1183\/20734735.0153-2022.","journal-title":"Breathe (Sheff)"},{"issue":"3","key":"3407_CR36","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/ehf2.13884","volume":"9","author":"K Bay","year":"2022","unstructured":"Bay K, Gustafsson F, Maiborg M, et al. Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review. ESC Heart Fail. 2022;9(3):1524\u201341. https:\/\/doi.org\/10.1002\/ehf2.13884.","journal-title":"ESC Heart Fail"},{"key":"3407_CR37","unstructured":"Amyloidosis Research Consortium. The Voice of the Patient. 2016. Accessed 19 July 2023. Available from: https:\/\/arci.org\/voice-of-the-patient\/"},{"key":"3407_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","volume":"304","author":"B Ladefoged","year":"2020","unstructured":"Ladefoged B, Dybro A, Povlsen JA, et al. Diagnostic delay in wild type transthyretin cardiac amyloidosis\u2014a clinical challenge. Int J Cardiol. 2020;304:138\u201343. https:\/\/doi.org\/10.1016\/j.ijcard.2019.12.063.","journal-title":"Int J Cardiol"},{"issue":"10","key":"3407_CR39","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jacc.2022.06.025","volume":"80","author":"M Grogan","year":"2022","unstructured":"Grogan M, Dispenzieri A. Carpal tunnel syndrome and cardiac amyloidosis when are numb hands a window to the heart? J Am Coll Cardiol. 2022;80(10):978\u201381. https:\/\/doi.org\/10.1016\/j.jacc.2022.06.025.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"3407_CR40","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/circulationaha.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312. https:\/\/doi.org\/10.1161\/circulationaha.116.021612.","journal-title":"Circulation"},{"issue":"2","key":"3407_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","volume":"27","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Ando Y, Bokhari S, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27(2):659\u201373. https:\/\/doi.org\/10.1007\/s12350-019-01761-5.","journal-title":"J Nucl Cardiol"},{"issue":"11","key":"3407_CR42","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","volume":"25","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. 2019;25(11):e1\u201339. https:\/\/doi.org\/10.1016\/j.cardfail.2019.08.001.","journal-title":"J Card Fail"},{"issue":"8","key":"3407_CR43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709\u201316. https:\/\/doi.org\/10.1016\/j.jchf.2019.04.010.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"3407_CR44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2217\/fca-2021-0122","volume":"18","author":"C Willis","year":"2022","unstructured":"Willis C, Watanabe AH, Hughes J, et al. Applying diagnosis support systems in electronic health records to identify wild-type transthyretin amyloid cardiomyopathy risk. Future Cardiol. 2022;18(5):367\u201376. https:\/\/doi.org\/10.2217\/fca-2021-0122.","journal-title":"Future Cardiol"},{"issue":"2","key":"3407_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.596.","journal-title":"J Am Coll Cardiol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03407-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03407-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03407-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:02:12Z","timestamp":1731085332000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03407-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3407"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03407-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3392956\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to participate was obtained through an introductory question contained in the survey and via verbal agreement prior to the interviews. The Western Copernicus Group Institutional Review Board approved both phases of the study (reference number: 1297323).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This was obtained via the survey and interviews.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CK has received honoraria for consulting for Takeda, Argenx, AstraZeneca, Sanofi, UCB, Alexion, Ionis, Neuroderm, Corino, and Alnylam. He has received research funding from Ionis and AstraZeneca. CM, CS, MPM and FMK are employees and stockholders of Alnylam Pharmaceuticals, Inc. LW, MP, MS, EJ and NM work on research studies contracted between their employer, Lumanity, and pharmaceutical company sponsors. As salaried employees, their compensation is not connected to the projects they work on. PS and MF are consultants on the Alnylam TTR Patient Advocacy Leadership Advisory Council and have not received any compensation or other type of funding specific to their involvement in the study reported here. MH has served on advisory boards for Pfizer, Alnylam, Eidos, Ionis, and Alexion Pharmaceuticals.No other disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"419"}}